These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38677101)

  • 1. Placebo response in patients with Dravet syndrome: Post-hoc analysis of two clinical trials.
    Devinsky O; Hyland K; Loftus R; Nortvedt C; Nabbout R
    Epilepsy Behav; 2024 Jul; 156():109805. PubMed ID: 38677101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dravet syndrome seizure frequency and clustering: Placebo-treated patients in clinical trials.
    Nabbout R; Hyland K; Loftus R; Nortvedt C; Devinsky O
    Epilepsy Behav; 2024 Jun; 155():109774. PubMed ID: 38643658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
    Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
    JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
    Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S;
    N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
    Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
    Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials.
    Madan Cohen J; Checketts D; Dunayevich E; Gunning B; Hyslop A; Madhavan D; Villanueva V; Zolnowska M; Zuberi SM
    Epilepsia; 2021 Sep; 62(9):2218-2227. PubMed ID: 34265088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
    Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
    JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.
    Devinsky O; Nabbout R; Miller I; Laux L; Zolnowska M; Wright S; Roberts C
    Epilepsia; 2019 Feb; 60(2):294-302. PubMed ID: 30582156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
    Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
    Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
    Zhang L; Li W; Wang C
    Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
    Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
    Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
    Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
    Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
    Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
    Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
    Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
    Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
    Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
    Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
    Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial.
    Scheffer IE; Halford JJ; Miller I; Nabbout R; Sanchez-Carpintero R; Shiloh-Malawsky Y; Wong M; Zolnowska M; Checketts D; Dunayevich E; Devinsky O
    Epilepsia; 2021 Oct; 62(10):2505-2517. PubMed ID: 34406656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.